Quick Facts: Therapeutic Domains

• May provide temporary relief for symptoms of the common cold or flu.
• Used to address discomfort associated with minor aches and pains, and headache.
• May assist in reducing fever.
• Aids in the temporary management of nasal and sinus congestion.
• May help control coughing due to minor throat irritation.

Contac is a non-prescription medication intended to help manage a range of common symptoms associated with colds and influenza. Its primary use is to provide temporary relief from general discomfort and minor aches, which may include headache and sore throat. This medication is typically used to support patient wellness during periods of seasonal illness.

Contac may also aid in the temporary management of fever. Additionally, it is used to address symptoms of upper respiratory irritation, which may involve assisting with the temporary control of a cough due to minor throat or bronchial irritation. The combination of ingredients may help to relieve symptoms like runny nose and sneezing, contributing to the desired therapeutic effect for a cold.

Regulatory References

1. NIH DailyMed guidance for Contac Cold + Flu Day Night

Eligibility for using Contac, a combination medicine typically containing Acetaminophen, Chlorphenamine Maleate, and Phenylephrine Hydrochloride, is strictly defined by regulatory guidelines based on age and pre-existing conditions.

Contraindicated Populations

Use is prohibited for:

• Individuals taking a Monoamine Oxidase Inhibitor (MAOI) or within two weeks of stopping one.
• Individuals with a known hypersensitivity to any of the product’s ingredients.
• Children under 4 years of age.

Age-Related Eligibility

Conditional Use Restrictions

Individuals with the following conditions must consult a doctor before use:

• Liver disease, heart disease, or high blood pressure.
• Diabetes, thyroid disease, or glaucoma.
• Trouble urinating due to an enlarged prostate gland.
• Breathing problems such as emphysema or chronic bronchitis.

Pregnancy and Lactation Status

Use during pregnancy or breastfeeding is not recommended, and individuals must ask a health professional before use.

Contac’s interaction profile is strictly defined by official regulatory labeling, encompassing formal prohibitions, timing rules, and exposure modifications based on its active ingredients: Chlorphenamine Maleate, Phenylephrine Hydrochloride, and Acetaminophen.

Formal Contraindications and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and a mandatory separation period of at least two weeks must follow the discontinuation of an MAOI. There is also a firm regulatory restriction against co-administration with any other product containing Acetaminophen due to the documented risk of cumulative dose-dependent hepatotoxicity.

Pharmacodynamic and Metabolic Interactions

The product may cause additive CNS depression when co-administered with Central Nervous System (CNS) Depressants, including opioid analgesics and hypnotics. Co-use with other Sympathomimetic Agents carries the risk of additive sympathomimetic effects, such as elevated heart rate and blood pressure. Alcohol (Ethanol) is prohibited as it potentiates CNS depression and significantly increases the risk of severe liver damage. Additionally, interactions with Strong CYP3A4 Inhibitors (e.g., Ketoconazole) may increase Chlorphenamine exposure, while CYP3A4 Inducers (e.g., Apalutamide) may decrease its systemic level. Co-administration with anticholinergic drugs may also intensify antimuscarinic actions.

Population-Specific Note

Official documentation notes that patients with chronic alcohol use or underlying liver disease have an increased susceptibility to the toxic effects of the Acetaminophen component.

Contac acts as a direct antagonist at the peripheral histamine H1-receptor. Its molecular structure facilitates binding to the H1-receptor, preventing the interaction of endogenous histamine with the receptor site. This competitive inhibition results in the termination of the Gq protein-coupled signaling cascade, which includes the inositol trisphosphate (IP3) and diacylglycerol (DAG) pathways. This downstream cellular consequence prevents the increase in intracellular calcium ions ( Ca^2+) that is typically triggered by histamine. Additionally, the compound modulates the release of inflammatory mediators from mast cells. The combined actions modify cellular and tissue-level responses to H1 activation, leading to systemic physiological modulation.

Official Administration Guidelines

Contac is an oral pharmaceutical preparation that follows a highly structured, label-based administration protocol.

The medicine is supplied as a fixed-dose combination (FDC) unit that must be swallowed whole with water; the solid form should not be crushed, chewed, or dissolved. This handling instruction is critical for the intended systemic delivery of the active compounds. Use is strictly designated as short-term, with specific time constraints. Administration for pain or congestion relief must not exceed seven days, while use for fever relief is restricted to three days. The standard adult regimen applies only to patients 12 years of age and older; consultation with a doctor is necessary for use in children under this age.

Procedural Structure Summary

The usage protocol establishes a defined sequence for administration: taking two units whole with water, adhering to the 4 to 6 hour interval, and rigorously respecting the daily maximum intake and the short-term duration limits. This highly specific procedural structure ensures the drug is utilized according to the standardized regimen.

Research Evidence / Overview of Studies for Contac

Evidence for Use in Common Cold and Flu-Like Syndrome

This section will summarize the structure of clinical trials, including randomized controlled trials (RCTs) and systematic reviews, that have studied how the combination relates to changes in measured cold and flu symptoms, such as fever, aches, and runny nose.

Research has primarily studied this combination medicine in the context of conditions characterized by fluctuating or episodic manifestations associated with acute common colds and flu-like illnesses. The main research design was evaluated in short-term, controlled studies where participants experiencing conditions involving periods of heightened symptoms were observed. These trials typically researched the combination of active ingredients (Acetaminophen, Chlorphenamine, and Phenylephrine) against a placebo to observe how patient-reported outcomes describing perceived discomfort evolved.

Studies report how symptoms evolved in the observed populations during the study period. This research examined whether there were measurable differences in Total Symptom Scores (TSS) and individual symptom ratings, such as fever and outcomes related to physical discomfort.

Long-Term Research and Follow-up Duration

Research exploring short-term symptom changes was observed in scenarios focused on the acute phase of illness. The follow-up durations in the trials were limited, generally lasting only 48 to 72 hours or up to 5 days. This means that the existing data primarily addresses research exploring short-term symptom changes when the medicine was studied for acute symptom activity.

As a result, long-term effects are not fully established. There is limited information for long-term outcomes or data that research describes the durability of symptom changes.

What is Still Uncertain or Limited in the Research

A key limitation involves the phenylephrine component (the decongestant). Findings indicate that scientific certainty regarding how symptoms respond to oral phenylephrine at standard over-the-counter doses for nasal congestion remains low. The U.S. FDA’s advisory groups have noted that the data do not show patterns related to symptom change for this specific ingredient at those doses.

Beyond this, evidence quality varies across studies of combination cold medicines. Sample sizes were modest in some instances, and follow-up durations were limited.

Key Studies & References Fixed-dose Combination Therapy of Paracetamol, Phenylephrine, and Chlorpheniramine Maleate for the Symptomatic Treatment of Common Cold in Indian Adults (Post-marketing surveillance study)

Common questions about Contac (FAQ)

Q: What is the difference between Contac and a regular pain reliever?

Official documents classify Contac as a Fixed-Dose Combination (FDC) medicine. This means it is formulated to contain multiple active ingredients, typically including an analgesic (pain reliever/fever reducer), an antihistamine, and a decongestant. In contrast, a regular pain reliever usually contains only one active ingredient for a single purpose.

Q: How long does the effect of Contac typically last?

The duration of effect depends on the specific product formulation. For forms designated as extended-release or sustained-release, the official product labeling indicates that the medicine is designed to provide symptomatic relief for up to 12 hours. Shorter-acting formulations are described in labeling as requiring use at more frequent intervals.

Q: Are there any food or drinks I should avoid while using Contac?

Official labeling states that the consumption of alcohol is strongly advised against, as it can increase the risk of liver damage and severe drowsiness due to the combined effects of the ingredients. No specific foods are routinely listed as prohibited; however, the medicine should always be used only as directed on the label.

Q: Is Contac a stimulant?

The decongestant component, Phenylephrine, is classified as a sympathomimetic agent. This type of ingredient is associated with side effects like nervousness or insomnia (sleeplessness), which are symptoms related to nervous system activity.

Q: Why do some people say they feel 'jittery' on Contac?

The feeling described as 'jittery' aligns with the reported side effects of the decongestant ingredient, which is a sympathomimetic agent. Common side effects listed in official documents include nervousness and insomnia. Less commonly, effects like palpitations (feeling the heart race or flutter) are also reported.

Q: What official bodies have approved Contac?

This type of pharmaceutical preparation is approved for sale and use by the official regulatory bodies in the country where it is marketed. In the United States, for instance, labeling and oversight are managed by the Food and Drug Administration (FDA). This approach is followed by comparable government agencies in other countries where the product is available.

Q: What are the signs of a serious reaction to Contac?

Official warnings describe the potential for serious adverse reactions. Signs that have been documented include severe allergic-type skin reactions, blistering of the skin, and symptoms associated with severe liver damage, such as yellowing of the skin or eyes.

Q: Is it safe to drive after taking Contac?

The official labeling carries a prominent warning regarding impairment. It is stated that due to the risk of drowsiness or sedation, caution must be exercised when driving or operating machinery.

Q: What is the evidence level for Contac's effectiveness?

Regulatory reviews indicate that overall evidence quality varies for combination cold medicines. Studies have examined the combination’s effect on various cold symptoms. Furthermore, for the oral decongestant component (Phenylephrine), regulatory bodies have noted that available data on measurable symptom improvement is considered limited.

Q: Is Contac an antibiotic?

No. According to its official classification, Contac is a combination of an analgesic (pain reliever/fever reducer), an antihistamine (for allergy and runny nose), and a sympathomimetic (decongestant) agent. It does not contain ingredients used to treat bacterial infections.

Q: How quickly should I expect Contac to start working?

The active ingredients are absorbed shortly after ingestion. Official scientific data for the components indicates that some absorption and effects are known to begin within 30 minutes of ingestion.

Q: Are there any common interactions between Contac and caffeine?

Because the product contains a decongestant (a sympathomimetic agent), regulatory documents recommend avoiding excessive intake of products containing caffeine. Both caffeine and the decongestant can act as stimulants and may cause additive effects such as increased blood pressure or heart rate.

Q: Can Contac interact with herbal supplements?

Official warnings detail interactions with specific drug classes, such as MAOIs and CNS depressants. Due to the potential for interactions, the labeling states that a health professional should be consulted if the user is taking any supplements.

Q: What happens if I miss a dose of Contac?

The product labeling does not provide specific instructions for managing a single missed dose. The labeling specifies taking the medicine as needed and adhering to the maximum daily limit, but it does not contain specific instructions for managing a single missed dose.

Q: Can Contac be taken with nasal spray?

Regulatory documents warn against co-use with other sympathomimetic agents, which includes many nasal spray decongestants. Using both an oral and nasal decongestant may lead to additive effects like increased heart rate or blood pressure, and consultation with a health professional is advised.

Q: Is Contac the same as Contac Cold & Flu?

Products marketed under brand names like 'Contac' or 'Contac Cold & Flu' generally contain the same or a very similar fixed-dose combination of active ingredients. Users should always check the Drug Facts label to verify the specific ingredients and ensure the intended formulation is used.

Q: What if Contac doesn't seem to be working for me?

The regulatory labeling specifies that if symptoms of pain or nasal congestion worsen or persist beyond 7 days, or if fever worsens or lasts more than 3 days, use should be discontinued and a health professional consulted. These time frames are critical limits outlined in the regulatory labeling.

Q: Can Contac be taken on an empty stomach?

The labeling specifies that the preparation is to be swallowed whole with water. While the labeling does not provide explicit instructions regarding whether the medicine must be taken with or without food, users should follow the administration route described.

Q: Is there a generic version of Contac?

Yes. Since this product contains widely available active ingredients (Acetaminophen, Chlorphenamine Maleate, and Phenylephrine), other products containing the same combination of ingredients are available. These may be marketed by other companies as generic equivalents.

Q: Is Contac considered a narcotic or controlled substance?

No. The product is officially classified by the FDA as an Over-the-Counter (OTC) combination medicine. It does not contain any ingredients that are currently classified as a Schedule I or II narcotic or controlled substance under the Controlled Substance Act (CSA) regulations.

Q: Why are there different versions of Contac (e.g., day/night)?

Different versions are formulated to manage symptoms appropriate for specific times of day. For example, 'Night' versions often contain an ingredient that causes drowsiness as a side effect, while 'Day' versions omit or substitute this ingredient to avoid daytime sedation.

Q: Does Contac have a risk of dependence?

Official drug product labeling does not include warnings regarding a risk of physical or psychological dependence. The components are not commonly associated with substance dependence when used strictly according to regulatory directions.

Q: What does 'contraindication' mean in relation to Contac?

In regulatory documents, a contraindication is a specific circumstance, condition, or factor that makes the use of the medicine potentially harmful or prohibited by the official directions. For example, severe liver disease or taking certain types of antidepressants (MAOIs) are listed as contraindications for Contac.

Q: What should I do if I suspect an interaction with Contac?

Official regulatory documents indicate that if an interaction is suspected, the use of the medicine should be discontinued immediately and a health professional consulted. For severe symptoms, the labeling advises seeking urgent medical help or contacting a Poison Control Center.

Q: Is Contac a brand name for something else?

Contac is a brand name used to market a specific combination of active ingredients. Its generic counterparts or other brands will be named based on the combination of ingredients, such as the Acetaminophen, Chlorphenamine, and Phenylephrine combination.

Q: Can Contac interfere with laboratory tests?

Some ingredients in the product, notably Acetaminophen, have been documented to potentially interfere with the accuracy of certain laboratory tests related to sugar or uric acid levels. If a user is scheduled for laboratory testing, the labeling indicates that a health professional should be notified about the use of this product.

Contac Cold + Flu must be stored according to regulatory specifications to maintain its stability and effectiveness.

Official Storage Conditions

Official Disposal Instructions

When disposing of unused or expired Contac, the preferred method is to use a drug take-back program or an authorized collector. If a take-back program is unavailable, the medication should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed bag before being discarded in the household trash. The product is not recommended for flushing down the toilet.